- Kurapa
- Uchapupu
- Neuroblastoma
- Gomarara Rakasimba
- Uchapupu
- TILS
- Kurapa Masero eNK
- Myasthenia Gravis (MG)
- Acute Lymphoblastic Leukemia (B-ALL)
- Systemic Lupus Erythematosus (SLE)
- Chirwere cheAcute Lymphoblastic Leukemia (T-ALL)
- Non Hodgkin Lymphoma (NHL)
- Multiple Myeloma (MM)
- Kuparadzira Lymphom yeB-cell yakakura
- B-lymphocytic Leukemia
- Myeloma
Kurapa kweCAR-T kweNon-Hodgkin Lymphoma (NHL)
Pfupiso
Non-Hodgkin Lymphoma (NHL) iboka rakasiyana-siyana rekenza yeropa rinobva mu lymphatic system, rine mhando dzakasiyana-siyana, dzinosanganisira B-cell neT-cell lymphomas. Pakati peizvi, Kupararira kweB-Cell Lymphoma (DLBCL) ndiyo mhando inonyanya kuzivikanwa uye ine hukasha yeB-cell NHL. Pasinei nekufambira mberi mukurapa chemotherapy ne immunotherapy, varwere vazhinji vane NHL yakadzokera shure kana isingashande vanotambura nesarudzo shoma dzekurapa. Kurapa kweCAR-T inopa nzira yekubudirira, ichipa tariro kuvarwere vane lymphoma isina kupindura kumishonga yechinyakare.
Chii chinonzi CAR-T Therapy yeNHL?
Kurapa neCAR-T (Chimeric Antigen Receptor T-cell) inzira itsva yekurapa nekudzivirira muviri inosanganisira kugadzirisa T-cells dzemurwere kuti dziite sereceptor inorwisa masero ane cancer. Kune NHL, CAR-T therapy inonyanya kunangana ne immunotherapy. CD19 uye CD20 maantigen ari pamasero eB, ayo anowanzo kuwanikwa pamasero elymphoma ane malignant. Nekuwedzera kugona kwemasero eT kuziva nekurwisa masero aya ekenza, CAR-T therapy inopa nzira inoshanda yekurapa varwere vane lymphoma yakadzoka kana kuti isingarapiki.
Mabhenefiti Akakosha eCAR-T Therapy yeNHL
- Inoshanda kune Relapsed uye Refractory NHL: Kurapa kweCAR-T kwakaratidza kushanda kwakanaka muvarwere vane DLBCL nedzimwe mhando dzeB-cell NHL vasina kupindura kurapwa kwakasiyana-siyana.
- Kunyatsonangwa Kwakanangana: Kurapa uku kunotarisa masero eB ane gomarara pasina kukuvadza masero ane hutano, zvichideredza migumisiro inowanzobatanidzwa nemishonga yechinyakare.
- Kurapwa Kwakasiyana Nevamwe: Kurapa kweCAR-T kunoshandisa maT-cell emurwere, zvichipa nzira yekurapa yakagadzirirwa mamiriro emunhu wacho.
- Mikana Yekuregerera Kwenguva Refu: Varwere vazhinji vakarerukirwa zvizere kana kuti zvishoma mushure mekurapwa neCAR-T, vamwe vachiramba vachirarama kwenguva refu, kunyangwe mushure mekurapwa kakawanda nechemotherapy.
Maitiro Ekurapa
- Muunganidzwa wemasero eT: Masero eT anotorwa kubva muropa remurwere kuburikidza nemaitiro anonzi leukapheresis, akafanana nekupa ropa.
- Kugadzira maT-cells: Murabhoritari, masero eT akaunganidzwa anogadziriswa majini kuti aratidze mareceptor anotarisa maantigen chaiwo akadai se CD19 kana CD20 inowanikwa pamasero elymphoma.
- Kupinzwa kweCAR-T: Kana maT-cell angowedzerwa uye agadziriswa, anodzoserwa muropa remurwere kuti arwise masero elymphoma.
- Kuongorora uye KuporaMushure mekuisirwa mushonga, varwere vanoongororwa kuti vaone kana paine migumisiro yakaipa, yakaita se cytokine release syndrome (CRS) uye neurotoxicity, zvese izvi zvinogona kurapwa nekubatsirwa kwakakodzera kwechiremba.
Sei Uchifanira Kusarudza BiocUS's CAR-T Therapy yeNHL?
- Tekinoroji yeCAR-T Yemazuva AnoBIOOCUS inoshandisa tekinoroji yeCAR-T yepamusoro-soro kupa mushonga wepamusoro uye unoshanda weNHL, ichishandisa tsvakiridzo yazvino kuti ive nechokwadi chekuti mhedzisiro yakanaka.
- Chikwata cheNyanzvi dzeHematology: Chikwata chedu chevanachiremba veropa, vanachiremba vekenza, uye nyanzvi dzekurapa zvirwere zvakasiyana-siyana vanoshanda pamwe chete kupa zvirongwa zvekurapa zvinoenderana nemunhu mumwe nemumwe.
- Kubudirira Kwakaratidzwa Mukurapa DLBCLBIOOCUS yakarapa varwere vakawanda veNHL neCAR-T therapy, zvichiita kuti pave nemhinduro dzinoshamisa, kusanganisira kurerukirwa zvizere uye kurarama kwenguva refu, kunyanya kune varwere vane DLBCL yakadzoka kana kuti isingashande zvakanaka.
- Rutsigiro Rwakazara rweVarwereKubva pakubvunzana kwekutanga kusvika pakutarisirwa mushure mekurapwa, BIOOCUS inopa rutsigiro rwakakwana kuvarwere vekune dzimwe nyika, ichivimbisa rwendo rwakatsetseka uye runotsigira panguva yese yekurapwa kwavo.
Uchapupu hweKliniki uye Mwero weKubudirira
-
Kurapa kweCAR-T kweNHL, kunyanya yeDLBCL, kwaratidza mhedzisiro yakanaka mukuyedzwa kwekiriniki uye kushandiswa kwayo chaiko. Kune varwere vakamborapwa nenzira dzakasiyana-siyana vasingabudirire, kurapwa kweCAR-T kwaratidza kuva sarudzo inoponesa hupenyu.
- Nyaya yeMurwere: Kupararira kweB-Cell Lymphoma (DLBCL)—Kupora Kunoshamisa Mushure mekurapwa neCAR-T
- Kubudirira Kwekiriniki: Kurapa kweCAR-T kweDLBCL Yakadzoka Muropa—Nzira Yekuregerera Kwakazara
- DLBCL Inodzivirira Mitsetse Yakawanda: Chidzidzo Chekushanda KweCAR-T Therapy muAdvanced Lymphoma
Zvidzidzo izvi zvinoratidza kugona kwekurapa kweCAR-T kune varwere vane NHL, kunyanya avo vane DLBCL inoramba kurapwa nehasha uye ine mitsetse yakawanda. Varwere vazhinji vakareruka kwenguva refu uye vawana hupenyu hwakanaka mushure mekurapwa.
Ruzivo rweKliniki
Zviratidzo zveCD19+20CAR-T:Varwere vane B-cell non Hodgkin's lymphoma
| Mwedzi mumwe chete CR rate | Mutengo wePR wemwedzi mumwe chete | Mwedzi mumwe chete OR chiyero | CRS≥3 | CRES≥3 |
| 71.95% (59/82) | 25.6 (21/82) | 97.55（80/82） | 12.19% (10/82) | 0 |
Zviratidzo zveCD19+22CAR-T:Kurapa kwevarwere vane chirwere cheCD19 vane chirwere cheB-lymphocytic leukemia chinodzoka shure uye chisingadzoreki
| Mwedzi mumwe chete CR rate | Mutengo wePR wemwedzi mumwe chete | Mwedzi mumwe chete OR chiyero | CRS≥3 | CRES≥3 |
| 92.1% (35/38) | 7.9% (3/38) | 100% (38/38) | 15.79% (6/38) | 0 |
Zviratidzo zveBCMACAR-T:Kurapa kwe multiple myeloma inodzokera shure uye isingadzoreki
| Mwedzi mumwe chete CR rate | Mutengo wePR wemwedzi mumwe chete | Mwedzi mumwe chete OR chiyero | CRS≥3 | CRES≥3 |
| 72.41% (21/29) | 27.59% (8/29) | 100% (29/29) | 6.9% (2/29) | 0 |
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.